Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab extension study in hematologic malignancies
2022-500765-27-00Phase 3Authorised
- Sponsor
- Incyte
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of tafasitamab in hematopoietic malignancies, sponsored by Incyte. Primary endpoint: Incidence and severity of SAEs, AESIs and selective AEs in patients receiving tafasitamab. Planned start Nov 2022; status: authorised.
02
Drugs
tafasitamab
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on 2022-500765-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500765-27-00.